The Feed
The Weight Number Was Never the Point. A New Trial Puts the Argument on the Record
A phase 2 trial published this year in Nature Medicine tested what happens when a muscle-preserving antibody is added to a GLP-1 drug. In 507 adults with obesity, the combination produced more total weight loss than the GLP-
The Glucose Monitor on Your Arm Is Producing Data Nobody Has Shown How to Use
A review of continuous glucose monitoring published this year in JAMA Internal Medicine reached a conclusion that sits awkwardly against how these devices are now marketed. In people who do not have diabetes, the authors found no scientific evidence that
Cellular Reprogramming Reached Its First Patients This Year. It Started in the Eye
In June, a company working on epigenetic reprogramming dosed the first patient in a phase 1 trial of a therapy called ER-100, aimed at two optic nerve conditions: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The
A New Gene Therapy Approval Shows What Accelerated Pathways Actually Ask For
In August the FDA granted accelerated approval to a one-time gene therapy for glycogen storage disease type Ia, a rare inherited disorder in which the body cannot release stored glucose properly and patients depend on carefully timed doses of
Federal PFAS Water Rules Are Shifting. The Household Layer Is Unchanged
In May, the EPA proposed two changes to the federal drinking water rule for PFAS compounds. One would extend the compliance deadline for the limits on PFOA and PFOS by two years, to 2031, for eligible water systems. The other
The Ingredient Layer Underneath Your Prescriptions Is Being Rebuilt Slowly
A policy analysis published at the end of August put a number on something the pharmaceutical supply chain has known for years. The United States produced roughly a quarter of the world's active pharmaceutical ingredients in the early
Lab-Grown Neurons Have Reached a Pivotal Parkinson's Trial. Here Is What That Actually Means
A cell therapy made from pluripotent stem cells is now in a registrational, sham-surgery-controlled trial for Parkinson's disease. The therapy, bemdaneprocel, consists of dopamine-producing neuron precursors grown in a lab and implanted surgically into the
A Metabolic Drug Was Tested Against Alzheimer's Disease. The Result Is Worth Understanding Clearly
Two large late-stage trials, evoke and evoke+, tested oral semaglutide, the same active compound behind the widely used GLP-1 medicines, in people with early symptomatic Alzheimer's disease. After two years of treatment, the drug did not
Join the Strategic Bio-Reserve
Institutional-grade intelligence on the next decade of biological power. Over 150,000+ experts securing the human code
